FY2017 Earnings Estimate for Edwards Lifesciences Corporation (EW) Issued By SunTrust Banks

Edwards Lifesciences Corporation (NYSE:EW) – Investment analysts at SunTrust Banks lifted their FY2017 earnings estimates for shares of Edwards Lifesciences Corporation in a research note issued on Wednesday. SunTrust Banks analyst B. Nudell now forecasts that the medical research company will earn $3.80 per share for the year, up from their previous estimate of $3.78. SunTrust Banks currently has a “Buy” rating and a $14.00 target price on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q4 2017 earnings at $0.95 EPS, Q1 2018 earnings at $1.12 EPS, Q3 2018 earnings at $0.96 EPS, Q4 2018 earnings at $1.04 EPS, FY2018 earnings at $4.21 EPS, FY2019 earnings at $4.78 EPS, FY2020 earnings at $5.38 EPS and FY2021 earnings at $5.91 EPS.

Several other equities research analysts also recently weighed in on EW. Cowen and Company reissued a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. Barclays PLC reissued an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Canaccord Genuity reissued a “buy” rating and set a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Jefferies Group LLC reissued a “buy” rating and set a $115.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $120.75.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/10/22/fy2017-earnings-estimate-for-edwards-lifesciences-corporation-ew-issued-by-suntrust-banks.html.

Shares of Edwards Lifesciences Corporation (EW) opened at 113.08 on Friday. The company has a market cap of $23.88 billion, a P/E ratio of 34.30 and a beta of 0.62. The stock’s 50 day moving average price is $111.15 and its 200-day moving average price is $111.91. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.76 earnings per share.

In related news, VP Donald E. Bobo, Jr. sold 25,000 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders sold a total of 201,161 shares of company stock valued at $22,826,072 over the last ninety days. 2.13% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. APG Asset Management N.V. increased its position in Edwards Lifesciences Corporation by 21.4% in the 3rd quarter. APG Asset Management N.V. now owns 66,444 shares of the medical research company’s stock valued at $7,263,000 after buying an additional 11,700 shares in the last quarter. Farmers & Merchants Investments Inc. increased its position in Edwards Lifesciences Corporation by 3.8% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 36,195 shares of the medical research company’s stock valued at $3,956,000 after buying an additional 1,330 shares in the last quarter. Oakbrook Investments LLC increased its position in Edwards Lifesciences Corporation by 25.7% in the 3rd quarter. Oakbrook Investments LLC now owns 19,050 shares of the medical research company’s stock valued at $2,082,000 after buying an additional 3,900 shares in the last quarter. Tributary Capital Management LLC increased its position in Edwards Lifesciences Corporation by 27.6% in the 3rd quarter. Tributary Capital Management LLC now owns 22,200 shares of the medical research company’s stock valued at $2,427,000 after buying an additional 4,800 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its position in Edwards Lifesciences Corporation by 3,036.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,070 shares of the medical research company’s stock valued at $226,000 after buying an additional 2,004 shares in the last quarter. 81.90% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products

Edwards Lifesciences Corporation (NYSE:EW) – Investment analysts at SunTrust Banks lifted their FY2017 earnings estimates for shares of Edwards Lifesciences Corporation in a research note issued on Wednesday. SunTrust Banks analyst B. Nudell now forecasts that the medical research company will earn $3.80 per share for the year, up from their previous estimate of $3.78. SunTrust Banks currently has a “Buy” rating and a $14.00 target price on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q4 2017 earnings at $0.95 EPS, Q1 2018 earnings at $1.12 EPS, Q3 2018 earnings at $0.96 EPS, Q4 2018 earnings at $1.04 EPS, FY2018 earnings at $4.21 EPS, FY2019 earnings at $4.78 EPS, FY2020 earnings at $5.38 EPS and FY2021 earnings at $5.91 EPS.

Several other equities research analysts also recently weighed in on EW. Cowen and Company reissued a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. Barclays PLC reissued an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Canaccord Genuity reissued a “buy” rating and set a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Jefferies Group LLC reissued a “buy” rating and set a $115.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $120.75.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/10/22/fy2017-earnings-estimate-for-edwards-lifesciences-corporation-ew-issued-by-suntrust-banks.html.

Shares of Edwards Lifesciences Corporation (EW) opened at 113.08 on Friday. The company has a market cap of $23.88 billion, a P/E ratio of 34.30 and a beta of 0.62. The stock’s 50 day moving average price is $111.15 and its 200-day moving average price is $111.91. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.76 earnings per share.

In related news, VP Donald E. Bobo, Jr. sold 25,000 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders sold a total of 201,161 shares of company stock valued at $22,826,072 over the last ninety days. 2.13% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. APG Asset Management N.V. increased its position in Edwards Lifesciences Corporation by 21.4% in the 3rd quarter. APG Asset Management N.V. now owns 66,444 shares of the medical research company’s stock valued at $7,263,000 after buying an additional 11,700 shares in the last quarter. Farmers & Merchants Investments Inc. increased its position in Edwards Lifesciences Corporation by 3.8% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 36,195 shares of the medical research company’s stock valued at $3,956,000 after buying an additional 1,330 shares in the last quarter. Oakbrook Investments LLC increased its position in Edwards Lifesciences Corporation by 25.7% in the 3rd quarter. Oakbrook Investments LLC now owns 19,050 shares of the medical research company’s stock valued at $2,082,000 after buying an additional 3,900 shares in the last quarter. Tributary Capital Management LLC increased its position in Edwards Lifesciences Corporation by 27.6% in the 3rd quarter. Tributary Capital Management LLC now owns 22,200 shares of the medical research company’s stock valued at $2,427,000 after buying an additional 4,800 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its position in Edwards Lifesciences Corporation by 3,036.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,070 shares of the medical research company’s stock valued at $226,000 after buying an additional 2,004 shares in the last quarter. 81.90% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply